According to Zacks, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. “
ADMP has been the topic of a number of other research reports. B. Riley upgraded Adamis Pharmaceuticals from a sell rating to a neutral rating in a report on Tuesday, July 23rd. Maxim Group set a $6.00 target price on Adamis Pharmaceuticals and gave the company a buy rating in a report on Friday, August 9th. ValuEngine upgraded Adamis Pharmaceuticals from a hold rating to a buy rating in a report on Saturday, August 10th. Dawson James initiated coverage on Adamis Pharmaceuticals in a report on Tuesday, July 2nd. They issued a buy rating on the stock. Finally, Raymond James set a $4.00 target price on Adamis Pharmaceuticals and gave the company a buy rating in a report on Friday, May 10th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $3.87.
Adamis Pharmaceuticals (NASDAQ:ADMP) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). The business had revenue of $5.77 million during the quarter, compared to analyst estimates of $5.82 million. Adamis Pharmaceuticals had a negative net margin of 205.32% and a negative return on equity of 86.04%. Sell-side analysts predict that Adamis Pharmaceuticals will post -0.46 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in ADMP. Morgan Stanley boosted its holdings in Adamis Pharmaceuticals by 189.7% in the second quarter. Morgan Stanley now owns 757,124 shares of the specialty pharmaceutical company’s stock worth $984,000 after acquiring an additional 495,793 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Adamis Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,791,266 shares of the specialty pharmaceutical company’s stock worth $2,328,000 after purchasing an additional 77,498 shares during the last quarter. A.R.T. Advisors LLC raised its stake in shares of Adamis Pharmaceuticals by 143.8% in the second quarter. A.R.T. Advisors LLC now owns 61,711 shares of the specialty pharmaceutical company’s stock worth $80,000 after purchasing an additional 36,400 shares during the last quarter. BlackRock Inc. raised its stake in shares of Adamis Pharmaceuticals by 1.5% in the second quarter. BlackRock Inc. now owns 962,687 shares of the specialty pharmaceutical company’s stock worth $1,252,000 after purchasing an additional 14,312 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Adamis Pharmaceuticals in the second quarter worth approximately $181,000. 19.49% of the stock is owned by institutional investors and hedge funds.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Featured Article: What does it mean to hold a stock in street name?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.